| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
| Asthenia | D001247 | 5 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Lymphoma, B-Cell | D016393 | 24 associated lipids |
| Breast Neoplasms | D001943 | 24 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Hyperplasia | D006965 | 34 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Gébleux R et al. | Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates. | 2015 | Mol. Cancer Ther. | pmid:26294742 |
| Hamblett KJ et al. | AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. | 2015 | Mol. Cancer Ther. | pmid:25931519 |
| Ab O et al. | IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. | 2015 | Mol. Cancer Ther. | pmid:25904506 |
| Golfier S et al. | Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. | 2014 | Mol. Cancer Ther. | pmid:24714131 |
| Andreev J et al. | Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs. | 2017 | Mol. Cancer Ther. | pmid:28108597 |
| Stefan N et al. | Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation. | 2017 | Mol. Cancer Ther. | pmid:28258164 |
| Lopus M et al. | Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. | 2010 | Mol. Cancer Ther. | pmid:20937594 |
| Oroudjev E et al. | Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. | 2010 | Mol. Cancer Ther. | pmid:20937595 |
| Zheng B et al. | In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. | 2009 | Mol. Cancer Ther. | pmid:19808977 |
| Singh R et al. | A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells. | 2016 | Mol. Cancer Ther. | pmid:27197308 |
| Yan H et al. | Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity. | 2016 | Mol. Cancer Ther. | pmid:26712117 |
| Cretella D et al. | Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. | 2014 | Mol. Cancer | pmid:24898067 |
| Werbovetz KA et al. | Purification, characterization, and drug susceptibility of tubulin from Leishmania. | 1999 | Mol. Biochem. Parasitol. | pmid:10029309 |
| Havens CG et al. | Cellular effects of leishmanial tubulin inhibitors on L. donovani. | 2000 | Mol. Biochem. Parasitol. | pmid:11071278 |
| Dagger F et al. | Regulatory volume decrease in Leishmania mexicana: effect of anti-microtubule drugs. | 2013 | Mem. Inst. Oswaldo Cruz | pmid:23440120 |
| Zuradelli M et al. | Never too old to fight breast cancer: A case report. | 2018 | Medicine (Baltimore) | pmid:29489698 |
| Vigne E and Sassoon I | [The growing field of immunoconjugates in oncology. A successful link(er) between antibodies and small cytotoxic molecules]. | 2014 | Med Sci (Paris) | pmid:25311020 |
| Haeuw JF et al. | [Immunoconjugates, drug-armed antibodies to fight against cancer]. | 2009 | Med Sci (Paris) | pmid:20035677 |
| Jordan A et al. | Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. | 1998 | Med Res Rev | pmid:9664292 |
| Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer. | 2013 | Med Lett Drugs Ther | pmid:24043217 | |
| Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer. | 2013 | Med Lett Drugs Ther | pmid:24662957 | |
| Mihály Z and Gyõrffy B | [HER2-positive breast cancer: available targeted agents and biomarkers for therapy response]. | 2013 | Magy Onkol | pmid:24107820 |
| Dank M and Tõkés T | [Monoclonal antibody therapy in breast cancer]. | 2013 | Magy Onkol | pmid:24107821 |
| Segraves NL et al. | An isolable acyclic hemiacetal of ansamitocin P-3. | 2012 | Magn Reson Chem | pmid:22374862 |
| Meng H et al. | A Smart Nano-Prodrug Platform with Reactive Drug Loading, Superb Stability, and Fast Responsive Drug Release for Targeted Cancer Therapy. | 2017 | Macromol Biosci | pmid:28464449 |
| Storz U | Antibody-drug conjugates: Intellectual property considerations. | 2015 | MAbs | pmid:26292154 |
| Panowski S et al. | Site-specific antibody drug conjugates for cancer therapy. | 2014 Jan-Feb | MAbs | pmid:24423619 |
| Beck A and Reichert JM | Antibody-drug conjugates: present and future. | 2014 Jan-Feb | MAbs | pmid:24423577 |
| Whiteman KR et al. | Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. | 2014 Mar-Apr | MAbs | pmid:24492307 |
| Chen L et al. | In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate. | 2016 | MAbs | pmid:27380163 |
| Beck A et al. | World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany. | 2011 Jul-Aug | MAbs | pmid:21691144 |
| Lutz RJ and Whiteman KR | Antibody-maytansinoid conjugates for the treatment of myeloma. | 2009 Nov-Dec | MAbs | pmid:20068397 |
| Beck A et al. | Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany. | 2012 Nov-Dec | MAbs | pmid:22909934 |
| Thudium K et al. | American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA. | 2013 Jan-Feb | MAbs | pmid:23255090 |
| Catcott KC et al. | Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates. | 2016 | MAbs | pmid:26752675 |
| Krop IE et al. | Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. | 2014 | Lancet Oncol. | pmid:24793816 |
| Gnant M et al. | HER2-positive breast cancer: a new piece of the puzzle. | 2014 | Lancet Oncol. | pmid:24793817 |
| Yaqub F | T-DM1 for HER2-positive metastatic breast cancer. | 2013 | Lancet Oncol. | pmid:23580966 |
| Montemurro F | Trastuzumab emtansine in HER2-positive metastatic breast cancer. | 2017 | Lancet Oncol. | pmid:28526537 |
| Krop IE et al. | Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. | 2017 | Lancet Oncol. | pmid:28526538 |
| Diéras V et al. | Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. | 2017 | Lancet Oncol. | pmid:28526536 |
| Hurvitz SA et al. | Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. | 2018 | Lancet Oncol. | pmid:29175149 |
| Thuss-Patience PC et al. | Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. | 2017 | Lancet Oncol. | pmid:28343975 |
| Venkatesa P | NICE recommends routine NHS funding for Kadcyla. | 2017 | Lancet Oncol. | pmid:28648556 |
| Elsada A et al. | NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer. | 2016 | Lancet Oncol. | pmid:26703893 |
| Venkatesan P | Trastuzumab emtansine for HER2-positive breast cancer. | 2016 | Lancet Oncol. | pmid:27866859 |
| Loibl S and Gianni L | HER2-positive breast cancer. | 2017 | Lancet | pmid:27939064 |
| Dholaria B and Srinivasan S | T-DM1-related carotenoderma and hand-foot syndrome. | 2015 | Lancet | pmid:25933279 |
| Kashiwaba M et al. | A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. | 2016 | Jpn. J. Clin. Oncol. | pmid:26917603 |
| Yamamoto H et al. | Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer. | 2015 | Jpn. J. Clin. Oncol. | pmid:25332421 |
| Okamoto K et al. | Therapeutic effect of ansamitocin targeted to tumor by a bispecific monoclonal antibody. | 1992 | Jpn. J. Cancer Res. | pmid:1517150 |
| Hayashi T et al. | Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. | 2015 | J. Urol. | pmid:26047983 |
| Fellous A et al. | Removal of the projection domain of microtubule-associated protein 2 alters its interaction with tubulin. | 1994 | J. Protein Chem. | pmid:7986343 |
| Xie H et al. | Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. | 2004 | J. Pharmacol. Exp. Ther. | pmid:14634038 |
| Kupchan SM et al. | The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides. | 1977 | J. Org. Chem. | pmid:874612 |
| Bartsch R et al. | Breast cancer brain metastases responding to primary systemic therapy with T-DM1. | 2014 | J. Neurooncol. | pmid:24065570 |
| Geraud A et al. | Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer. | 2017 | J. Neurooncol. | pmid:27995546 |
| de Vries CL et al. | Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1. | 2016 | J. Neurooncol. | pmid:26732082 |
| Altundag K | Radio-sensitising effect of T-DM1 should not be discarded for the efficacy of radiosurgery in the management of brain metastases in patients with HER2-positive metastatic breast cancer. | 2017 | J. Neurooncol. | pmid:28337582 |
| Sato Y et al. | Induction of neurofibrillary tangles in cultured mouse neurons by maytanprine. | 1985 | J. Neurol. Sci. | pmid:4040155 |
| Cosmai L et al. | Renal toxicity of anticancer agents targeting HER2 and EGFR. | 2015 | J. Nephrol. | pmid:26341657 |
| Alabaster O and Cassidy M | Flow microfluorometric analysis of P388 murine leukemia after administration of vincristine and maytansine in vivo. | 1978 | J. Natl. Cancer Inst. | pmid:625068 |
| Eagan RT et al. | Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication. | 1978 | J. Natl. Cancer Inst. | pmid:628025 |
| Schwarz LJ et al. | An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. | 2017 | J. Natl. Cancer Inst. | pmid:29059433 |
| Azvolinsky A | Conjugating antibodies to cytotoxic agents: getting the best of both worlds? | 2013 | J. Natl. Cancer Inst. | pmid:24244034 |
| Tuma RS | Enthusiasm for antibody-drug conjugates. | 2011 | J. Natl. Cancer Inst. | pmid:21972230 |
| Gupta RS | Species-specific differences in toxicity of antimitotic agents toward cultured mammalian cells. | 1985 | J. Natl. Cancer Inst. | pmid:3855475 |
| Aldrich CD | Pleiotropic phenotype of cultured murine cells resistant to maytansine, vincristine, colchicine, and adriamycin. | 1979 | J. Natl. Cancer Inst. | pmid:224236 |
| Askoxylakis V et al. | Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. | 2016 | J. Natl. Cancer Inst. | pmid:26547932 |
| Sakai K et al. | Antitumor principles in mosses: the first isolation and identification of maytansinoids, including a novel 15-methoxyansamitocin P-3. | 1988 Sep-Oct | J. Nat. Prod. | pmid:3204376 |
| Novelo M et al. | Cytotoxic constituents from Hyptis verticillata. | 1993 | J. Nat. Prod. | pmid:8277312 |
| Perdue RE | KB cell culture I. Role in discovery of antitumor agents from higher plants. | 1982 Jul-Aug | J. Nat. Prod. | pmid:7130986 |
| Kusari S et al. | Endophytes are hidden producers of maytansine in Putterlickia roots. | 2014 | J. Nat. Prod. | pmid:25478947 |
| Snipes CE et al. | The ansacarbamitocins: polar ansamitocin derivatives. | 2007 | J. Nat. Prod. | pmid:17892263 |
| Tan GT et al. | Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. | 1991 Jan-Feb | J. Nat. Prod. | pmid:1710653 |
| Kuo YH et al. | Antitumor agents, 112. Emarginatine B, a novel potent cytotoxic sesquiterpene pyridine alkaloid from Maytenus emarginata. | 1990 Mar-Apr | J. Nat. Prod. | pmid:2380715 |
| Kupchan SM et al. | Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids. | 1978 | J. Med. Chem. | pmid:563462 |
| Zhao RY et al. | Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. | 2011 | J. Med. Chem. | pmid:21517041 |
| Pillow TH et al. | Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. | 2014 | J. Med. Chem. | pmid:25191794 |
| Lambert JM and Chari RV | Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. | 2014 | J. Med. Chem. | pmid:24967516 |
| Widdison WC et al. | Semisynthetic maytansine analogues for the targeted treatment of cancer. | 2006 | J. Med. Chem. | pmid:16821799 |
| Ng D et al. | Constitutive overexpression of asm2 and asm39 increases AP-3 production in the actinomycete Actinosynnema pretiosum. | 2009 | J. Ind. Microbiol. Biotechnol. | pmid:19609582 |
| Gao Y et al. | Enhancement of ansamitocin P-3 production in Actinosynnema pretiosum by a synergistic effect of glycerol and glucose. | 2014 | J. Ind. Microbiol. Biotechnol. | pmid:24174216 |
| Dillon RL et al. | Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance. | 2016 | J. Immunother. | pmid:26938945 |
| Tanida S et al. | Ansamitocin-induced synchrony in Tetrahymena pyriformis. | 1980 | J. Gen. Microbiol. | pmid:6777454 |
| Yue W et al. | Induction of apoptosis in hormone refractory breast cancer: horizontal modulation is superior to vertical. | 2013 | J. Exp. Ther. Oncol. | pmid:24416991 |
| La Monica S et al. | Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. | 2017 | J. Exp. Clin. Cancer Res. | pmid:29202823 |
| Feng L et al. | Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. | 2016 | J. Exp. Clin. Cancer Res. | pmid:27102688 |
| Krop IE et al. | Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. | 2015 | J. Clin. Oncol. | pmid:25713436 |
| Hurvitz SA et al. | Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. | 2013 | J. Clin. Oncol. | pmid:23382472 |
| Harbeck N et al. | De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. | 2017 | J. Clin. Oncol. | pmid:28682681 |
| Giordano SH et al. | Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. | 2014 | J. Clin. Oncol. | pmid:24799465 |
| Moore KN et al. | Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. | 2017 | J. Clin. Oncol. | pmid:28029313 |
| Isakoff SJ and Baselga J | Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. | 2011 | J. Clin. Oncol. | pmid:21172881 |
| Burris HA et al. | Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. | 2011 | J. Clin. Oncol. | pmid:21172893 |
| Force J et al. | Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. | 2016 | J. Clin. Oncol. | pmid:24778392 |
| Krop IE et al. | Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. | 2010 | J. Clin. Oncol. | pmid:20421541 |
| Krop IE et al. | A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. | 2012 | J. Clin. Oncol. | pmid:22649126 |
| Perez EA et al. | Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. | 2017 | J. Clin. Oncol. | pmid:28056202 |
| Hassan R et al. | Mesothelin Immunotherapy for Cancer: Ready for Prime Time? | 2016 | J. Clin. Oncol. | pmid:27863199 |